Effects of raloxifene, hormone therapy, and soy isoflavone on serum high-sensitive C-reactive protein in postmenopausal women

International Journal of Gynecology and Obstetrics

Volumn 90, Issue 2, 2005, Pages 128-133

  Yildiz, M Fahrettin ^a   Kumru, Selahattin ^a,b   Godekmerdan, Ahmet ^a   Kutlu, Selim ^a  

^a FIRAT UNIVERSITY   (Turkey)

^b Universite Mah Yahya Kemal Bulv   (Turkey)

Author keywords

Dienogest; Estradiol valerate; High sensitive C reactive protein; Hormone therapy; Raloxifene; Soy isoflavones

Indexed keywords

C REACTIVE PROTEIN; DIENOGEST PLUS ESTRADIOL VALERATE; GENISTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HORMONE; ISOFLAVONE; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; RALOXIFENE; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HEMOCONCENTRATION; HORMONAL THERAPY; HUMAN; LIPID ANALYSIS; NORMAL HUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE;

EID: 22144474371     PISSN: 00207292     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijgo.2005.05.005     Document Type: Article

References (25)

1. C.J. Rosen, and C.R. Kessenich The pathophysiology and treatment of post-menopausal osteoporosis: an evidence-based approach to estrogen replacement therapy Endocrinol Metab Clin North Am 26 1997 295 311
2. G.A. Greendale, N.P. Lee, and E.R. Arriola The menopause Lancet 353 1999 571 580
3. R.T. Chlebowski, S.L. Hendrix, R.D. Langer, M.L. Stefanick, M. Gass, and D. Lane Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the women's health initiative randomized trial JAMA 289 2003 3243 3253
4. F.B. Hu, and F. Grodstein Postmenopausal hormone therapy and the risk of cardiovascular disease: the epidemiologic evidence Am J Cardiol 90 2002 26 29
5. S. Hulley, D. Grady, T. Bush, C. Furberg, D. Herrington, B. Riggs Heart and Estrogen/progestin Replacement Study (HERS) Research Group Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women JAMA 280 1998 605 613
6. G.L. Anderson, M. Limacher, A.R. Assaf, T. Bassford, S.A. Beresford, and H. Black Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the women's health initiative randomized controlled trial JAMA 291 2004 1701 1712
7. I. Jialal, S. Devaraj, and S.K. Venugopal C-reactive protein: risk marker or mediator in atherothrombosis? Hypertension 44 2004 6 11
8. P.M. Ridker, N. Rifai, L. Rose, J.E. Buring, and N.R. Cook Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events N Engl J Med 347 2002 1557 1565
9. G. Liuzzo, and V. Rizzello C-reactive protein and primary prevention of ischemic heart disease Clin Chim Acta 311 2001 45 48
10. P.M. Ridker, E. Julie, C.B. Shih, M. Matias, and C.H. Hennekens Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women Circulation 98 1998 731 733
11. H. Yu, and N. Rifai High-sensitivity C-reactive protein and atherosclerosis: from theory to therapy Clin Biochem 8 2000 601 610
12. A.W. Haider, R. Roubenoff, P.W. Wilson, D. Levy, R. D'Agostino, and H. Silbershatz Monocyte cytokine production, systemic inflammation and cardiovascular disease in very elderly men and women: the Framingham heart study Eur J Cardiovasc Prev Rehabil 11 2004 214 215
13. J.M. Backes, P.A. Howard, and P.M. Moriarty Role of C-reactive protein in cardiovascular disease Ann Pharmacother 38 2004 110 118
14. M. Frohlich, N. Muhlberger, H. Hanke, A. Imhof, A. Doring, and M.B. Pepys Markers of inflammation in women on different hormone replacement therapies Ann Med 35 2003 353 361
15. W. Vongpatanasin, M. Tuncel, Z. Wang, D. Arbique, B. Mehrad, and I. Jialal Differential effects of oral versus transdermal estrogen replacement therapy on C-reactive protein in postmenopausal women J Am Coll Cardiol 41 2003 1358 1363
16. B.W. Walsh, S. Paul, R.A. Wild, R.A. Dean, R.P. Tracy, and D.A. Cox The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial J Clin Endocrinol Metab 85 2000 214 218
17. K.D. Setchell Phytoestrogens: the biochemistry, physiology, and implications for human health of soy isoflavones Am J Clin Nutr 68 1998 1333 1346
18. G.G. Kuiper, B. Carlsson, and K. Grandien Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β Endocrinology 138 1997 863 870
19. N. Colacurci, R. Zarcone, A. Borrelli, P. De Franciscis, N. Fortunato, and M. Cirillo Effects of soy isoflavones on menopausal neurovegetative symptoms Minerva Ginecol 56 2004 407 412
20. E. Nikander, M. Metsa-Heikkila, A. Tiitinen, and O. Ylikorkala Evidence of a lack of effect of a phytoestrogen regimen on the levels of C-reactive protein, E-selectin, and nitrate in postmenopausal women J Clin Endocrinol Metab 88 2003 5180 5185
21. H.J. Teede, F.S. Dalais, and B.P. McGrath Dietary soy containing phytoestrogens does not have detectable estrogenic effects on hepatic protein synthesis in postmenopausal women Am J Clin Nutr 79 2004 396 401
22. T. Gröser, H. Hoffmann, and M. Oettel Climodien: a new oral preparation for continuous combined hormone replacement therapy in postmenopausal women Drugs Today 37 2001 17 27
23. J.A. Belfaur, and K.L. Goa Raloxifene Drugs Aging 4 1998 335 341
24. S. Nanda, N. Gupta, H.C. Mehta, and K. Sangwan Effect of oestrogen replacement therapy on serum lipid profile Aust N Z J Obstet Gynaecol 43 2003 213 216
25. I.S. Ödmark, T. Backström, M. Haegar, B. Jonsson, and M. Bixo Effects of continuous combined conjugated estrogen/medroxyprogesteron acetate and 17 Beta estradiol/norethisterone acetate on lipids and lipoproteins Maturitas 48 2004 137 146